27 Jun, EOD - Indian

Nifty Pharma 21928.6 (0.55)

Nifty Smallcap 100 18976.8 (0.91)

Nifty IT 38822.95 (-0.44)

Nifty Next 50 68712.4 (0.61)

SENSEX 84058.9 (0.36)

Nifty Bank 57443.9 (0.41)

Nifty 50 25637.8 (0.35)

Nifty Midcap 100 59385.15 (0.27)

27 Jun, EOD - Global

NIKKEI 225 40150.79 (1.43)

HANG SENG 24284.15 (-0.17)

S&P 6232.75 (0.41)

LOGIN HERE

companylogoCipla Ltd

You are Here : Home > Markets > CompanyInformation > Company Background
BSE Code : 500087 | NSE Symbol : CIPLA | ISIN : INE059A01026 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |


Chairman's Speech

Dear Shareholders,

On 17th August, 1935, our founder, Dr K A Hamied, established the Chemical, Industrial & Pharmaceutical Laboratories Ltd. with a vision, determination and a deep empathy for humanity. The company was later renamed 'Cipla'. Over the decades, Cipla has provided access to affordable, high-quality medicines - not only in India, but globally.

Today, Cipla remains fully committed to its purpose of 'Caring for Life'.

In 2025, we proudly complete nine decades of service to society. Throughout this journey, Cipla has consistently prioritised science, R&D and innovation, while maintaining a humanitarian approach to its business. From humble beginnings, Cipla has grown into one of India's leading pharmaceutical companies. Our purpose reflects our core belief, "Success does not make a company great. What really matters is its contribution to society and improving the lives of our fellowmen."

The Cipla journey has travelled side by side with my own life, as I will soon turn 90 in mid-2026.1 have been involved with the Company virtually since inception. It has been a long and arduous association, but at the same time very fruitful. In all humility,

I feel extremely proud of my years in Cipla and my own personal role in Cipla's evolution.

There are two words I would like to share with everyone. The first is "Imagination", a quality that differentiates people, especially scientists. The second and perhaps more important, is "Enthusiasm", the

passion for what one is pursuing in life, is what really matters. Even after nearly 70 years in the pharmaceutical industry, I am still deeply enthusiastic, particularly in the areas of R&D, new product launches and future innovations. All of this is aimed towards Cipla's progress and growth, as also to help communities and alleviate the sufferings of patients.

Cipla's endeavour has always been 'Caring for Life' and therefore, each one of you, our shareholders, indirectly contribute to this mission.

Our respiratory portfolio helps millions breathe freely. The anti-retroviral drugs made by us have saved innumerable lives of those suffering from HIV/AIDS, essentially in Africa. Cipla provides care when there is no cure. Via its Palliative Care initiatives, Cipla has supported thousands of patients and their families in India over the past three decades. I would like to reiterate that Cipla's purpose is not only business-driven, but also has a humanitarian approach. We strive to make a meaningful impact towards the healthcare needs of society.

We want to contribute to newer technologies, advanced medication, so that we can expand our product portfolio to enable a better quality of life for everyone.

The intrinsic strength of Cipla lies in its people, both past and present.

From a small team in our early years, we now have a global workforce of nearly 30,000. I feel proud to share that the dedication, passion, resilience and sense of purpose shown by one and all, has been ongoing over the years and we all uphold the strong values on which our Company has been built. The accomplishments we have achieved so far are a testament to the unwavering support we have received, both in the past and present, as also the collaborative spirit of all our partners including the

invaluable support that we continue to receive from the medical community and pharmacies. We also have to acknowledge the strategic guidance of our Company's Management team, the Cipla Board of Directors and above all, the trust and faith our shareholders have in our Company.

To one and all, I extend my personal appreciation, as also that of Cipla.

We have come a long way from a modest beginning in 1935 to becoming a leading international pharmaceutical company. Cipla will continue to pioneer, innovate, care and contribute to the welfare of all. Hopefully, Cipla will preserve and uphold its legacy in the years ahead and continue its strategic progress and growth in the future.

I would like to express my deepest gratitude to Mr M K Hamied, whose visionary leadership has been instrumental in shaping Cipla's journey. Mr Hamied played a pivotal role in steering Cipla's progress and though he has formally retired, he continues to offer invaluable guidance on humanitarian matters. On behalf of everyone at Cipla, we extend our heartfelt thanks to him and wish him continued good health and well-being

Finally, I would like to thank each one of you, our shareholders and the Cipla family for being part of our ongoing journey.

Warm regards,

Y K Hamied

Chairman

   

Capital Market Publishers India Pvt. Ltd

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071, India.

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

Copyright @ Capital Market Publishers India Pvt.Ltd

Designed, Developed and maintained by CMOTS Infotech (ISO 9001:2015 Certified)

Site best viewed in Internet Explorer Edge ,   Google Chrome 115.0.5790.111 + ,   Mozilla Firefox 115.0.3 + ,   Opera 30.0+, Safari 16.4.1 +